Shots:

• The P-III CHOICE-01 trial evaluates toripalimab + CT vs PBO + CT in 465 patients in a ratio (2:1) with advanced sq./nonsq. NSCLC. The results of the study will be presented at WCLC 2021
• Results: improvement in PFS with m-PFS (8.3 vs 5.6mos.)- m-OS (21.0 vs 16.0mos.). In sq. & nonsq. NSCLC patients - ORR (68.7% vs 58.9%) & (58.6% vs 26.5%)- m-DoR (6.9 vs 4.2mos.) & (8.6 vs 5.1mos.)- no new safety signal identified- discontinuation due to AEs (12.3% vs 1.9%) respectively
• The companies plan to discuss with US FDA for the submission of toripalimab’s BLA to treat NSCLC. Additionally- a rolling submission of 1st BLA for recurrent or metastatic NPC is ongoing in the US

  | Ref: Coherus | Image: Coherus